2921 KB29 KB200520252022Avsec, DamjanMlinarič-Raščan, IrenaPodgornik, Helenaštevilka:1letnik:73str. 31-39ISSN:0014-8229COBISSID_HOST:103039747URN:URN:NBN:SI:doc-JEU4H14XslSlovensko farmacevtsko društvoFarmacevtski vestnikApoptozaBcl-2Kronična limfocitna levkemijanavitoklaksobatoklaksS55746venetoklaksTarčno zdravljenje kronične limfocitne levkemije z antagonisti antiapoptotičnih proteinov| Antagonists of antiapoptotic proteins in the targeted therapy of chronic lymphocytic leukemia|Chronic lymphocytic leukemia is the most common leukemia among adults in the Western world, and is characterised by the progressive accumulation of monoclonal B lymphocytes in the blood, bone marrow and lymphatic organs. For decades, the treatment was based on chemotherapy and chemoimmunotherapy, which have been almost entirely replaced by the small targeted molecules over the past decade. These act on either the B cell receptor pathway or the antiapoptotic protein Bcl-2. Apoptosis is an imporatant process for the homeostasis of B lymphocytes, with antiapoptotic proteins from the Bcl-2 family playing a central role. Because the maintenance of malignant B lymphocytes depends on antiapoptotic proteins, antagonists of these proteins represent important drugs in the fight against chronic lymphocytic leukemia. In this review, we present the development, significance and future of antagonists of antiapoptotic proteins in the targeted treatment of chronic lymphocytic leukemiaKronična limfocitna levkemija je najpogostejša levkemija pri odraslih v Zahodnem svetu, za katero je značilno kopičenje monoklonskih limfocitov B v krvi, kostnem mozgu in limfatičnih organih. Desetletja je zdravljenje temeljilo na kemoterapiji in kemoimunoterapiji, ki so ju v zadnjem desetletju skoraj v celoti nadomestile majhne tarčne molekule. Te delujejo bodisi na receptorsko pot celic B bodisi na antiapoptotični protein Bcl-2. Apoptoza je ključen proces v homeostazi limfocitov B, pri čemer osrednjo vlogo igrajo antiapoptotični proteini iz družine Bcl-2. Ker je vzdrževanje malignih limfocitov B odvisno od antiapoptotičnih proteinov, predstavljajo njihovi antagonisti pomembne učinkovine v boju s kronično limfocitno levkemijo. V tem pregledu predstavljamo razvoj, pomen in prihodnost antagonistov antiapoptotičnih proteinov v tarčnem zdravljenju kronične limfocitne levkemijeTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo